September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Clinical efficacy of generic versus branded latanoprost for primary open angle glaucoma
Author Affiliations & Notes
  • Diana H Kim
    Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
  • James A Shaffer
    Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Brian L VanderBeek
    Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
    Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics & Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Diana Kim, None; James Shaffer, None; Brian VanderBeek, None
  • Footnotes
    Support  K23-EY025729
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2601. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Diana H Kim, James A Shaffer, Brian L VanderBeek; Clinical efficacy of generic versus branded latanoprost for primary open angle glaucoma. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2601.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The efficacy of generic latanoprost compared to that of brand-name latanoprost in treating primary open-angle glaucoma (POAG) has not been widely established. To better understand differences in their respective abilities to treat POAG, we assessed a cohort of incident POAG patients taking branded or generic latanoprost using a national claims database to determine the risk of needing a second intraocular pressure (IOP) medication or surgical intervention.

Methods : This was a retrospective cohort study using medical claims data from a large, national U.S. insurer. Cohorts were created using all incident POAG patients (defined as a new ICD9 for POAG and a prescription fill for either generic or branded latanoprost within 30 days of diagnosis) from 2000-2013. Index date was considered the date of diagnosis. Exclusion criteria included less than 2 years of time in the plan prior to diagnosis, any previous use of a glaucoma medication or any diagnosis of any form of glaucoma other than POAG prior to or after the index date. Outcomes of interest were need for a second IOP-lowering medication and need for surgical intervention. Cox proportional hazard models were used to calculate covariate-adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs) for comparing medication and procedure outcomes in the generic vs. branded drug groups. Covariates of interest were age, sex, race, education level and financial net worth.

Results : A total of 1,853 patients met the criteria for study eligibility (948 treated with generic; 905 treated with branded). The rate of secondary IOP prescription was 19.6% for generic vs. 25.2% for branded (HR: 0.82, 95% CI: 0.66, 1.02). The rate of procedural intervention was 5.5% for generic and 8.6% for branded (HR: 0.68, 95% CI: 0.46, 1.01). Combined, the rate of secondary IOP prescription and/or procedural intervention was 22.2% in for generic and 29.2% for branded (HR: 0.80, 95% CI: 0.65, 0.98).

Conclusions : Generic latanoprost was no less efficacious in preventing the need for a second IOP medication or surgical intervention than its brand-name counterpart. Further work will be needed to understand why the results suggest that the generic form is more effective than its branded counterpart.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×